Ardelyx Inc
Company Profile
Business description
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Contact
400 Fifth Avenue
Suite 210
WalthamMA02451
USAT: +1 510 745-1700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
395
Stocks News & Analysis
stocks
Earnings Winners: BHP, NAB & TLS lead the pack
stocks
Walmart earnings: Growth in digital buoys margin amid consumer trade-down
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,316.60 | 23.80 | -0.25% |
| CAC 40 | 8,398.78 | 30.25 | -0.36% |
| DAX 40 | 25,043.57 | 234.64 | -0.93% |
| Dow JONES (US) | 49,395.16 | 267.50 | -0.54% |
| FTSE 100 | 10,627.04 | 59.14 | -0.55% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,682.73 | 70.91 | -0.31% |
| Nikkei 225 | 57,467.83 | 323.99 | 0.57% |
| NZX 50 Index | 13,405.85 | 38.35 | -0.29% |
| S&P 500 | 6,861.89 | 19.42 | -0.28% |
| S&P/ASX 200 | 9,086.20 | 24.30 | -0.27% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |